| Tabella 1. Caratteristiche dei pazienti | |
| N = 40 pazienti · Linfomi | |
| Characteristic | N = 401 |
|---|---|
| Diagnosi | |
| DLBCL | 19 (48%) |
| DLBCL double HIT | 1 (2.5%) |
| FL | 1 (2.5%) |
| MCL | 7 (18%) |
| PMBCL | 7 (18%) |
| s-DLBCL | 5 (13%) |
| Età alla diagnosi | 59 (50, 64) |
| Ecog basale | |
| 0 | 17 (44%) |
| 1 | 16 (41%) |
| 2 | 5 (13%) |
| 3 | 1 (2.6%) |
| Terapia 1ª linea | |
| CHT | 2 (5.0%) |
| GMALL | 1 (2.5%) |
| O-CHOP | 1 (2.5%) |
| PROMACE-CYTABOM | 1 (2.5%) |
| R-BENDA | 1 (2.5%) |
| R-CHOP | 12 (30%) |
| R-CHOP / R-DAOX | 1 (2.5%) |
| R-CHOP + lena | 1 (2.5%) |
| R-CHOP/R-DAOX | 5 (13%) |
| R-CHOP14 | 1 (2.5%) |
| R-COMP | 7 (18%) |
| R-COMP-14 | 1 (2.5%) |
| R-DHAP | 1 (2.5%) |
| R-HYPER-CVAD | 2 (5.0%) |
| R-POLA-CHP | 2 (5.0%) |
| R-POLA-CHP + HD MTX | 1 (2.5%) |
| Terapia 2ª linea | |
| BRENTUXIMAB-NIVOLUMAB | 1 (2.5%) |
| IBRUTINIB | 5 (13%) |
| IMBRUVICA | 1 (2.5%) |
| MARIETTA | 2 (5.0%) |
| NA | 11 (28%) |
| Obinotuzumab-Benda | 1 (2.5%) |
| PEMBROLIZUMAB | 1 (2.5%) |
| R-DHAOx | 2 (5.0%) |
| R-DHAP | 10 (25%) |
| R-GEMOX | 3 (7.5%) |
| R-ICE | 1 (2.5%) |
| R-IEV | 1 (2.5%) |
| RT | 1 (2.5%) |
| Terapia 3ª linea | |
| NA | 34 (85%) |
| PEMBROLIZUMAB | 1 (2.5%) |
| PIXANTRONE | 1 (2.5%) |
| R-BAC | 1 (2.5%) |
| R-DHAOx | 1 (2.5%) |
| R-GEMOX | 1 (2.5%) |
| R-IEV | 1 (2.5%) |
| Autotrapianto | |
| NA | 1 (2.5%) |
| NO | 32 (80%) |
| SI | 7 (18%) |
| Allotrapianto | |
| NA | 4 (10%) |
| NO | 36 (90%) |
| Linee pre-CART (senza bridge) | |
| 1 | 11 (28%) |
| 2 | 22 (55%) |
| 3 | 6 (15%) |
| 5 | 1 (2.5%) |
| Terapia bridge | |
| NO | 8 (20%) |
| SI | 32 (80%) |
| Tipo terapia bridge | |
| IBRUTINIB | 2 (5.0%) |
| NA | 5 (13%) |
| NO | 2 (5.0%) |
| PEMBROLIZUMAB | 1 (2.5%) |
| PIRTOBRUTINIB | 1 (2.5%) |
| PIXANTRONE | 2 (5.0%) |
| PIXANTRONE + R-IEV | 1 (2.5%) |
| R-BAC | 1 (2.5%) |
| R-DHAP | 1 (2.5%) |
| R-GEMOX | 5 (13%) |
| R-GEMOX + RT | 1 (2.5%) |
| R-IBRUTINIB-VENETOCLAX | 1 (2.5%) |
| R-IEV | 2 (5.0%) |
| R-LENALIDOMIDE | 2 (5.0%) |
| R-POLA | 2 (5.0%) |
| R-POLA-BENDAMUSTINA | 2 (5.0%) |
| R-POLA-CHP | 2 (5.0%) |
| RT | 6 (15%) |
| RT + R-POLA | 1 (2.5%) |
| Ecog a CAR-T | 24 (63%) |
| Prodotto CAR-T | |
| AXICEL | 25 (63%) |
| BREXUCABTAGENE AUTOLEUCEL | 6 (15%) |
| TECARTUS | 1 (2.5%) |
| TISAGENLECLEUCEL | 8 (20%) |
| Status malattia alla CART | |
| PD | 29 (73%) |
| PR | 4 (10%) |
| RC | 1 (2.5%) |
| SD | 6 (15%) |
| Tossicità ematologica | |
| 0 | 17 (44%) |
| 1 (ferritina) | 1 (2.6%) |
| 1 (PCR) | 3 (7.7%) |
| 1 (PLT) | 1 (2.6%) |
| 2 (Fe PCR) | 2 (5.1%) |
| 2 (Gb PCR) | 1 (2.6%) |
| 2 (Hb PCR) | 1 (2.6%) |
| 2 (PLT PCR) | 1 (2.6%) |
| 2 (Plt) | 1 (2.6%) |
| 2 (PLT) | 2 (5.1%) |
| 3 (Hb+Fe+PCR) | 2 (5.1%) |
| 3 (PLT Fe) | 1 (2.6%) |
| 4 (Hb Fe PCR) | 1 (2.6%) |
| 4 (Hb PLT Fe PCR) | 1 (2.6%) |
| 5 | 1 (2.6%) |
| 6 (Hb Gb PLT PCR Fe) | 1 (2.6%) |
| 6 (Hb PLT PCR Fe) | 1 (2.6%) |
| 7 (Hb PLT N Fe PCR) | 1 (2.6%) |
| 1 n (%); Median (Q1, Q3) | |
CART Cell – Analisi di sopravvivenza
Linfomi · Pescara
1 Caratteristiche dei pazienti
2 Risultati di sopravvivenza
2.1 Mediane
| Mediane di sopravvivenza con IC 95% | |||||
| Endpoint | N pazienti | N eventi | Mediana (mesi) | IC 95% inf. | IC 95% sup. |
|---|---|---|---|---|---|
| Overall Survival | 40 | 17 | 36.1 | 10.4 | NR |
| Relapse-Free Survival | 40 | 16 | 22.1 | 11.0 | NR |
| Time to Next Treatment | 40 | 11 | 36.1 | 11.0 | NR |
| Follow-up mediano | 40 | 23 | 18.0 | 6.5 | 28.5 |
| NR = non raggiunto | |||||
2.2 Overall Survival
2.3 Relapse-Free Survival
2.4 Time to Next Treatment
2.5 Cumulative Incidence of Relapse
2.6 RMST – Overall Survival
| Restricted Mean Survival Time – Overall Survival | |||
| Mesi medi di sopravvivenza entro l'orizzonte τ | |||
| τ..mesi. | RMST | IC 95% inf. | IC 95% sup. |
|---|---|---|---|
| 12 | 8.7 | 7.2 | 10.2 |
| 24 | 15.0 | 11.6 | 18.4 |
| 36 | 21.3 | 15.7 | 26.9 |
| RMST calcolato con metodo Kaplan-Meier · IC 95% = RMST ± 1.96 × SE | |||
2.7 Partitioned Survival Analysis
2.8 Surrogacy PFS → OS
2.9 Markov multi-state model
